In COVID-19 clinical update #118, Dr. Griffin discusses management of hair loss after infection, FDA announcements on vaccine schedule and recommendations, Moderna announcement on bivalent booster candidate, association between vaccination and infection during pregnancy, population-level implications of Israel’s booster campaign, PAXLOVID outcomes during recent infection surge, efficacy and safety of Tixagevimab-cilgavimab, diagnostic accuracy of infection by canines, efficacy of colchicine in hospitalized patients, and factors associated with hospital readmission.  

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Management of hair loss after infection (NIH)
• FDA announces vaccine schedule meeting (FDA)
• FDA advisory committee recommends NOVAVAX vaccine (Novavax)
• Moderna announces bivalent booster candidate (Moderna)
• Association of vaccination and infection during pregnancy (JAMA)
• Implications of Israeli booster campaign (Science Translational Medicine)
• PAXLOVID patient eligibility screening checklist (FDA)
• Remdesivir fact sheet for providers (Veklury) 
• Bebtelovimab fact sheet for providers (FDA)
• PAXLOVID outcomes during infection surge (Research Square)
• Efficacy and safety of Tixagevimab–cilgavimab (The Lancet)
• Diagnostic accuracy of infection by canines (PLOS ONE)
• Efficacy of colchicine in hospitalized patients (Nature)
• Factors associated with readmission (IDSA) 
• Contribute to FIMRC fundraiser at PWB
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 908
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]